Thyroid-Associated Diseases and Functions in Kidneys, Lungs, and Spleen
| Tissue | Time point | Disease and function | Annotation | P | Molecule |
| Kidney cortex | 1 h | ND | |||
| 6 h | Endocrine system disorders | Familial primary hyperparathyroidism | 1.1E−02 | CYP24A1 | |
| Cancer, endocrine system disorders | Parathyroid cancer | 1.9E−02 | CYP24A1 | ||
| Endocrine system disorders | Secondary hyperparathyroidism | 2.7E−02 | CYP24A1 | ||
| 24 h | ND | ||||
| 7 d | ND | ||||
| Kidney medulla | 1 h | ND | |||
| 6 h | ND | ||||
| 24 h | Cancer, endocrine system disorders | Thyroid cancer | 3.5E−04 | ABCC3,LGALS3,NCOA4,PRLR,RB1,SLPI,SOCS3,SPHK1,SPP1,STAT3,TIMP1,TIMP3 | |
| Cancer, endocrine system disorders | Papillary thyroid cancer | 5.0E−04 | ABCC3,LGALS3,NCOA4,SPHK1,SPP1,TIMP1,TIMP3 | ||
| Cancer, endocrine system disorders | Epithelial thyroid cancer | 6.5E−04 | ABCC3,LGALS3,NCOA4,PRLR,RB1,SPHK1,SPP1,STAT3,TIMP1,TIMP3 | ||
| Endocrine system development and function, organ development | Activation of thyroid gland | 9.3E−04 | GHR,HPN,PRF1 | ||
| 7 d | ND | ||||
| Lungs | 1 h | ND | |||
| 6 h | ND | ||||
| 24 h | ND | ||||
| 7 d | ND | ||||
| Spleen | 1 h | Cancer, endocrine system disorders | Incidence of medullary thyroid carcinoma | 3.8E−03 | PRLR |
| 6 h | Endocrine system disorders, immunologic disease, inflammatory disease | Hashimoto thyroiditis | 5.8E−05 | CD83,CTLA4 | |
| Endocrine system disorders, immunologic disease, inflammatory disease | Susceptibility to Hashimoto thyroiditis | 3.0E−03 | CTLA4 | ||
| 24 h | Cell morphology, endocrine system development and function, organ morphology, organismal development | Abnormal morphology of thyroid follicle cells | 2.5E−02 | CTSK | |
| 7 d | ND |
ND = not detected.
Pathways were generated with IPA software; analysis was performed using NEXUS Expression output files of significantly regulated transcripts in response to 1.7–1.8 kBq of 211At at respective time points.